SERM comparison reference

Raloxifene vs Tamoxifen: Comparing Two SERMs for Breast Cancer Prevention

Both belong to the same class. Both bind estrogen receptors. But they differ on populations, side-effect profiles, and the cancers they treat versus prevent. A clear-eyed comparison based on the STAR trial and decades of data.

Speak with a Hormone Specialist Read the guide →

Educational reference · Reviewed by clinicians · Last updated May 2026

Comparative illustration of raloxifene and tamoxifen medications

What Are SERMs?

SERM stands for Selective Estrogen Receptor Modulator. SERMs are non-steroidal molecules that bind to estrogen receptors but produce different effects in different tissues — sometimes mimicking estrogen, sometimes blocking it. The key clinical insight that came out of decades of SERM research is that the same drug can be a “friend” to one tissue (such as bone) while being an “enemy” to another (such as estrogen-driven breast cancer cells).

Tamoxifen and raloxifene are the two SERMs most widely used in US medicine. They are related molecules with overlapping but distinct profiles, and they have been studied head-to-head in the largest SERM comparison trial ever conducted (STAR).

Tamoxifen: Brief Overview

Tamoxifen has been on the market since 1977 and is one of the most studied medications in oncology. Its primary uses:

Treatment of hormone-receptor-positive breast cancer (both pre- and postmenopausal);
Adjuvant therapy after surgery for hormone-receptor-positive breast cancer;
Risk reduction in women at increased risk of breast cancer (pre- and postmenopausal).

Mechanistically, tamoxifen blocks estrogen receptors in breast tissue. In premenopausal women, it does not affect bone density meaningfully and can sometimes accelerate bone loss. In postmenopausal women, tamoxifen has modest bone-protective effects, although it is not approved for osteoporosis.

The key downside of tamoxifen in postmenopausal women is its effect on the uterine lining — tamoxifen acts as a weak estrogen agonist in the endometrium, slightly increasing the risk of endometrial cancer. It also raises the risk of cataracts and venous thromboembolism.

Raloxifene: Brief Overview

Raloxifene entered the market in 1997, originally for the prevention and treatment of postmenopausal osteoporosis. In 2007, the FDA expanded its indications to include the reduction of invasive breast cancer risk in postmenopausal women at increased risk.

Raloxifene’s defining characteristic is its tissue selectivity: agonist in bone, antagonist in breast tissue, and largely neutral in the uterus. This profile gives raloxifene two advantages in the postmenopausal population: bone preservation and a much lower endometrial cancer risk than tamoxifen.

It is not approved for premenopausal women, not approved for treating existing breast cancer, and not effective for menopausal symptoms.

Side-by-Side: Tamoxifen vs Raloxifene

A practical comparison of the two SERMs across the dimensions that matter most for patients deciding between them or already on one.

Feature	Tamoxifen	Raloxifene
Drug class	SERM (Selective Estrogen Receptor Modulator)	SERM (Selective Estrogen Receptor Modulator)
FDA approval year	1977 (treatment), later expanded to prevention	1997 (osteoporosis), 2007 (breast cancer risk reduction)
Approved patient populations	Pre- and postmenopausal women; also men	Postmenopausal women only
Approved for treating existing breast cancer?	Yes	No
Approved for osteoporosis?	No (bone-protective but not approved indication)	Yes (prevention and treatment)
Effect on uterine cancer risk	Increases risk in postmenopausal women	No significant increase
Effect on bone density (postmenopausal)	Modest preservation	Significant preservation
Hot flash incidence	Common	Common
Venous thromboembolism risk	Elevated, somewhat higher than raloxifene in postmenopausal women	Elevated, especially first 4 months
Cataract risk	Increased	Not increased
Typical dose	20 mg daily	60 mg daily
Treatment duration (risk reduction)	5 years	≥5 years, often longer for osteoporosis

The STAR Trial: Head-to-Head Comparison

The Study of Tamoxifen and Raloxifene (STAR / NSABP P-2) enrolled 19,747 postmenopausal women at increased risk of breast cancer and randomized them to either tamoxifen 20 mg daily or raloxifene 60 mg daily, with follow-up for several years.^[1][2]

Key findings:

Invasive breast cancer: raloxifene was nearly as effective as tamoxifen — retaining about 76% of tamoxifen’s benefit (longer follow-up suggested somewhat lower equivalence, around 76–78%).
Non-invasive breast cancer (DCIS, LCIS): tamoxifen was modestly more effective.
Uterine cancer: tamoxifen significantly increased the risk; raloxifene did not.
Blood clots (DVT, PE): both raised the risk, but tamoxifen significantly more so.
Cataracts: tamoxifen increased the risk; raloxifene did not.
Hysterectomies: more frequent in the tamoxifen arm, driven largely by endometrial changes.
Quality of life and overall mortality: similar between groups.

The practical conclusion that emerged from STAR: in postmenopausal women at increased breast cancer risk, raloxifene offers a slightly smaller invasive-cancer benefit but a meaningfully better safety profile. This shifted clinical practice toward raloxifene for risk reduction in postmenopausal women, while tamoxifen remained the choice in premenopausal women and in women being treated for existing breast cancer.

Who Should Choose Tamoxifen?

Tamoxifen is generally the right choice for:

Premenopausal women at increased breast cancer risk;
Women being treated for hormone-receptor-positive breast cancer (adjuvant or metastatic);
Women who have undergone hysterectomy (the uterine cancer risk no longer applies);
Women in whom raloxifene is contraindicated for non-cancer reasons but who still need SERM risk reduction.

Who Should Choose Raloxifene?

Raloxifene is generally the better fit for:

Postmenopausal women at increased breast cancer risk who still have a uterus;
Postmenopausal women who need both breast cancer risk reduction and osteoporosis protection;
Women particularly concerned about uterine cancer, cataracts, or clot risk relative to baseline.

Raloxifene is not appropriate for:

Premenopausal women;
Women with prior DVT, PE, or retinal vein thrombosis;
Women whose primary problem is menopausal symptom relief.

Deciding between two SERMs is a serious conversation.

Choosing between raloxifene and tamoxifen depends on your menopausal status, breast cancer risk numbers, uterine and clot history, and how you weigh side effects against benefits. A hormone-trained provider can walk you through the trade-offs.

Discuss Your Options with a Specialist

US-licensed providers · Confidential consultation · No obligation

Beyond SERMs: Other Risk Reduction Options

SERMs are not the only tools. Depending on your situation, your clinician may also discuss:

Aromatase inhibitors (anastrozole, exemestane) — for postmenopausal women at high risk, often more effective than SERMs for risk reduction but with their own side-effect profile (joint pain, bone loss).
Lifestyle modifications — alcohol moderation, weight management, regular exercise, balanced nutrition — all of which contribute measurably to lifetime breast cancer risk and overall health.
Risk-reducing surgery — bilateral mastectomy and/or salpingo-oophorectomy in carefully selected women with very high genetic risk (e.g., BRCA1/BRCA2 carriers).
Hormone therapy considerations — for women without elevated breast cancer risk who are weighing the broader hormonal picture, this becomes a separate conversation entirely. The raloxifene alternatives page covers the broader landscape.

The right combination of strategies usually depends on your specific risk numbers (Gail score, Tyrer-Cuzick model, genetic testing where appropriate), bone status, and personal priorities. A clinician who specializes in women’s hormonal health is well positioned to put it all together rather than addressing each piece in isolation.

Raloxifene vs Tamoxifen: FAQ

The questions most often asked when choosing between or switching between SERMs.

Is raloxifene or tamoxifen better at preventing breast cancer?

In the head-to-head STAR trial of postmenopausal women at increased risk, tamoxifen was modestly more effective at preventing invasive breast cancer; raloxifene retained roughly 76% of tamoxifen’s effectiveness. However, raloxifene caused fewer uterine cancers, fewer blood clots, fewer cataracts, and fewer hysterectomies. For most postmenopausal women, the trade-off favors raloxifene.

Can premenopausal women take raloxifene?

No. Raloxifene is approved only for postmenopausal women. Premenopausal women at increased breast cancer risk are typically considered for tamoxifen instead. Aromatase inhibitors and other approaches are not generally used in premenopausal risk reduction without ovarian suppression.

Does raloxifene treat existing breast cancer?

No. Raloxifene is not approved for treating breast cancer. Tamoxifen is widely used both to prevent breast cancer in high-risk women and to treat existing hormone-receptor-positive breast cancer. If you have an active diagnosis, your oncologist will recommend the right SERM, aromatase inhibitor, or other therapy.

Which has fewer side effects, raloxifene or tamoxifen?

Both SERMs share certain side effects, particularly hot flashes and clot risk. Tamoxifen carries a meaningfully higher risk of uterine cancer, cataracts, and DVT/PE in postmenopausal women. Raloxifene’s side-effect burden is generally lower in postmenopausal use, which is why it has become the more common choice for chemoprevention in that population.

Can I switch from tamoxifen to raloxifene?

Some women do switch — typically once they enter menopause, since raloxifene’s safety profile becomes a better fit. The decision should be made with an oncologist or hormone-trained clinician who can weigh the breast cancer risk profile, years of prior therapy, and any side-effect issues that prompted the question.

How long is each medication taken for?

Tamoxifen for risk reduction is typically prescribed for 5 years. For treatment of breast cancer, courses can extend to 10 years. Raloxifene for risk reduction is generally taken for at least 5 years, often longer. For osteoporosis, raloxifene is continued as long as the benefit outweighs the ongoing risks.

Does either drug affect bone density?

Both have estrogen-like effects on bone in postmenopausal women and can help preserve bone density. Raloxifene is FDA-approved for osteoporosis prevention and treatment in postmenopausal women; tamoxifen has bone-protective effects in postmenopausal women but is not approved for osteoporosis. In premenopausal women, tamoxifen can actually accelerate bone loss.

Are there alternatives to both SERMs for breast cancer prevention?

Yes. Aromatase inhibitors (anastrozole, exemestane) are an option for postmenopausal women at increased risk and may be more effective than SERMs for that population. Lifestyle interventions — alcohol moderation, weight management, regular exercise — also contribute meaningfully to risk reduction. For very high genetic risk, risk-reducing surgery is sometimes considered.

References

This page draws on peer-reviewed clinical trials, FDA labeling, and position statements from US and international medical societies. Citations link to authoritative primary sources.

Vogel VG, et al. JAMA 2006;295(23):2727-2741 — STAR Trial primary — Study of Tamoxifen and Raloxifene — direct head-to-head
Vogel VG, et al. Cancer Prev Res 2010;3(6):696-706 — STAR long-term update — Updated results at median 81 months follow-up
Fisher B, et al. J Natl Cancer Inst 1998;90(18):1371-1388 — NSABP P-1 — Original tamoxifen prevention trial
USPSTF: Medication Use to Reduce Risk of Breast Cancer (2019) — Evidence-based recommendation including both SERMs